Skip to main content

Out-of-Stock Medicines: Pharmacy Queries and Substitution Records

When a chemist reports an unavailable medicine, capture the original prescription and the exact proposed alternative, including ingredients, strength, formulation, release characteristics and route. A clinician or appropriately authorised professional must review the change within the applicable rules. Record the decision, revise affected instructions and clarify what the patient actually received; similar names or dose arithmetic alone do not establish equivalence.

By Bractis · Updated · 16 min read

Indian clinic doctors, reception teams and pharmacists handling out-of-stock products, alternative strengths and supply-related prescription clarification.

Turn the pharmacy call into a precise question

“The usual brand is unavailable; can we give the other one?” hides several possible changes. The alternative may have the same ingredient and strength, a different strength, another release formulation or an additional ingredient. Before seeking a decision, identify what is actually being proposed and which prescription version the pharmacy is reading.

Reception can collect information and route the query without approving a clinical substitution. Record the caller’s role, pharmacy and callback route, the patient and prescription reference, the unavailable item and the proposed supply. Avoid collecting unrelated patient details over an unverified call.

If the product is unclear, request appropriate label or packaging information through the clinic’s agreed channel. Preserve uncertainty. A confident transcription of an incomplete brand name does not create evidence of the ingredients or formulation.

Compare the entire product identity, not just the leading word

Read the ingredients and strengths from a reliable source, including every ingredient in a fixed-dose combination. Check the strength basis, dosage form, route and any modified-release or other formulation distinction. Device or administration requirements may also matter for products such as insulin and inhalers.

A matching ingredient does not resolve every suitability question. The clinician considers the intended indication, patient circumstances, the current regimen and the specific proposed product. This article does not establish a universal Indian legal authority for brand substitution or a rule permitting every pharmacy to change a prescription.

If the proposal is a different treatment because the original is unavailable, describe it as a new clinical decision. Calling it a substitution should not hide the need to reassess the plan, explain the change and update monitoring or follow-up where relevant.

NHS Specialist Pharmacy Service guidance identifies product information and brand-specific administration instructions as relevant when considering formulation changes. Its published context is swallowing difficulties in UK practice. Here it supports checking the actual presentation; it is not authority to apply UK substitution rules or manipulation instructions in an Indian clinic.

Source: NHS SPS: Checking if tablets can be crushed or capsules opened

Worked shortage case: compare three proposals for one prescription line

This fictional case concerns a two-item prescription P1 issued by an Indian clinic. At 10:10, the chemist reports that the product on line 1 is unavailable locally; line 2 is not part of the query. The ingredient letters and proposal names below are teaching labels, not actual medicines. Real strengths, doses and treatment directions are deliberately omitted, so the example cannot be used as a prescription or an interchangeability list.

The clinic confirms the pharmacy callback route and the P1 version being read. At 10:25, it has three proposed product descriptions with readable labels and relevant manufacturer information for the reviewer. Proposal A has the original ingredient and printed strength but a different release formulation. Proposal B adds another active ingredient. Proposal C has a different brand name while matching the recorded ingredient, strength and its basis, tablet form, release characteristics and oral route.

The comparison below contains four rows because the original is the reference, followed by three proposals. It does not rank products by availability or price. Nor does it treat matching fields as sufficient evidence of clinical suitability: the responsible prescriber still evaluates the actual product information, current patient circumstances and intended treatment. If an identifying field remains unreadable, the reviewer should see that gap instead of a completed “same medicine” label.

In this fictional case, the prescriber authorises Proposal C for line 1 at 10:45 after that review. Proposals A and B are not authorised for this request. This is one patient-specific decision, not a general declaration that either proposal is always unsuitable or that every same-ingredient brand can be exchanged. A request to split, crush, open or otherwise alter a presentation would need its own product-specific review; no such manipulation is approved here.

On a narrow screen, scroll the table horizontally to read all columns.

Fictional product comparison: the unavailable original and three pharmacy proposals
Product being comparedIdentity evidence in this exampleDifference requiring a decision
Original line 1Ingredient X; recorded strength per tablet; immediate-release tablet for oral useReference identity from P1; local unavailability is a reported supply problem
Proposal AIngredient X and the same printed strength; modified-release oral tabletRelease characteristics differ; equal printed strength does not settle the change
Proposal BIngredient X plus Ingredient Y; oral tabletAn additional active ingredient changes the proposed treatment; the original line cannot describe the whole product
Proposal CDifferent brand; recorded ingredient, strength and its basis, tablet form, immediate release and oral route matchMatching fields support review but do not themselves authorise supply; exact C is accepted only after the fictional prescriber’s assessment

Classify what changes before reviewing the answer

Use this original query matrix to organise the handover. It helps the reviewer identify the missing evidence; it is not an equivalence table. Several rows can apply to the same proposed product, so do not force a complicated query into one reassuring category.

On a narrow screen, scroll the table horizontally to read all columns.

Medicine supply queries and the evidence needed for review
Proposed changeDetails to establishAssumption to avoid
Different brandFull identity, strength, formulation, route and relevant product informationThe same leading ingredient guarantees the same instructions
Different strengthClinician-approved amount, usable presentation and revised patient directionsSimple multiplication authorises a new regimen
Tablet splittingExact product labelling, suitability and ability to follow the reviewed planEvery scored or similar-looking tablet can be split
Different release formulationRelease characteristics and clinical appropriatenessAn equal printed strength makes formulations interchangeable
Combination instead of single ingredientEvery ingredient and overlap with current medicinesThe familiar brand word means nothing else changed
Different delivery deviceExact presentation, patient ability and teaching needsThe old device instructions remain applicable
Partial supplyQuantity actually dispensed and the plan for the remainderA smaller pack silently changes treatment duration

Keep arithmetic separate from suitability and authorisation

A numerical relationship between strengths is not sufficient to approve a change. The formulation may not support splitting, the patient may struggle with the new instructions or the proposed product may differ in another important respect. First establish suitability and authorisation, then document the precise instruction the clinician approves.

FDA tablet-splitting guidance advises checking the specific product information and notes that many sustained, controlled or timed-release products are not intended for splitting, with exceptions only where supported by the product information. Its US regulatory context is not an Indian dispensing rule. The relevant lesson for this workflow is to verify the actual product rather than assuming that a score line or another brand’s behaviour settles the question.

A changed tablet count also affects how long a dispensed quantity lasts. The revised instructions and supply record need to agree, but the calculation should follow the approved plan. Do not let a dispensing quantity automatically determine a new duration or taper phase.

Source: FDA: Tablet Splitting

Return a complete answer to the pharmacy and patient

The response should state whether the proposal was accepted, declined or remains unresolved, and who made that decision. If accepted, identify the exact product and revised instructions. A message saying only “OK” can become detached from the product photograph or refer to an earlier proposal in the conversation.

Update the prescription through the clinic’s approved process and label its relationship to the earlier version. Tell the patient which copy applies and what to do with any older supply according to the clinician’s plan. Do not erase the original prescription or assume that changing the digital record changes a paper copy already held at the pharmacy.

Where a decision is urgent because treatment access is affected, route it through the clinic’s clinical escalation process. An administrative callback target is not a clinical guarantee that the patient can safely wait. Record the action agreed by the responsible professional rather than inventing a universal deadline for all medicines.

Distinguish proposed, authorised, dispensed and taken

These are four separate states. A proposed alternative is a question. An authorised change records a decision. A dispensing confirmation describes what was supplied. Patient-reported use describes what happened afterward. A record can contain one without establishing the others.

If the patient has already received or taken a different product, obtain the actual identity and reported use for clinical review. Document the discrepancy and the resulting advice. Correcting the future prescription does not resolve any clinical consequences of earlier exposure, and a stock adjustment should not overwrite the patient’s history.

For partial supply, record the quantity actually received and the plan for the balance. Check whether another pharmacy, another pack or a revised clinical plan is involved. Keep those decisions explicit so that a later refill request is not mistaken for excess use or a completed course.

Change the affected line and reconcile the quantity actually supplied

The prescriber issues replacement P2 with both prescription lines visible: line 1 names the authorised Proposal C, while line 2 retains its earlier instruction unchanged. Thus two lines remain in the current document, but only one line has changed. Sending a cropped image of the changed line would make it harder for the patient or another pharmacist to determine whether the other medicine had also been withdrawn or replaced.

In the fictional supply record, P2 authorises a total quantity of 12 tablets for line 1. This is a counting example only; the amount per administration and duration are not supplied. At 10:55 the pharmacy acknowledges the exact P2 product and version. At 11:15 it reports dispensing 5 tablets of C, with 7 still outstanding: 12 minus 5 equals 7. The five tablets do not become five treatment days, and the seven outstanding tablets do not become a missed-dose count.

An approval and a dispensing report answer different questions. The prescriber’s acceptance of C does not prove that twelve tablets were available, that five provide adequate coverage until more stock arrives, or that line 2 was supplied. The coordinator routes the short-supply information back to the clinician, who accepts the access question at 11:20. The pharmacy also accepts responsibility for clarifying the remaining seven. At the 11:30 cutoff, both answers are still pending.

At 11:25, the patient confirms receipt of a pharmacy packet, but actual use has not yet been established. The note should not convert that acknowledgement into “treatment started” or “all medicines received”. Record the source of the five-tablet count as the pharmacy’s dispensing confirmation and distinguish it from what the patient has personally checked. A UPI receipt, delivery message or order marked complete is not a substitute for product, quantity and use evidence.

On a narrow screen, scroll the table horizontally to read all columns.

Fictional shortage handover at 11:30: evidence changes one state at a time
EventWhat is establishedWhat remains unproven or open
10:45 — P2 authorisedC accepted for line 1; line 2 unchanged; line 1 quantity 12 tabletsNo dispensing or patient-use outcome follows from authorisation
10:55 — pharmacy acknowledgementPharmacy identifies the exact C product and P2 versionAcknowledgement does not show full stock or completed supply
11:15 — dispensing confirmationPharmacy reports 5 tablets of C supplied; documentary balance 7Duration, actual patient use and line 2 supply are not established
11:20 — outstanding work acceptedClinician accepts access review; pharmacy accepts remaining-supply clarificationNeither a revised clinical decision nor fulfilment of the balance is recorded
11:25 — patient acknowledgementPatient reports receipt of a packetExact contents independently checked by the patient and administration history are not established

Use a closed-loop medicine clarification record

The following original outline keeps the question, evidence and answer together. It can be used on paper or in a clinic record. Distinguish a completed clarification handover from a resolved supply problem: the pharmacy may have acknowledged the decision while the patient’s access question remains open. Assigning an owner does not mean the outstanding work is complete.

Leave a usable note for the next clinician or pharmacy callback

A useful note names the exact accepted proposal instead of saying “alternative approved”. In a busy OPD, three photographs can arrive in the same message thread and an isolated “OK” can be attached to the wrong image. Retain the proposal-to-decision link, the original prescription and the complete replacement. Explain the changed line to the patient in their preferred language while keeping the verified medicine identity readable for the dispensing team.

In this example, P2 has been sent to the patient through the agreed contact route, but comprehension of the replacement is not yet confirmed at 11:30. The coordinator owns obtaining the patient’s account of the packet, routing any uncertainty to the clinician and confirming that the applicable instruction reaches any agreed family helper. The person forwarding a message is not automatically the person receiving or taking the medicine.

If another pharmacy offers the balance, transfer the current decision and confirmed supply history rather than restarting the request as though nothing was supplied. A different brand, formulation or strength from that pharmacy creates a new question; approval of C is not open permission to use any available product. Reconcile later confirmations against the seven outstanding tablets without silently changing the earlier five-tablet entry.

The clinician determines whether the access problem requires an immediate response or a revised plan. The timestamps below describe a fictional sequence, not a safe waiting interval. Do not promise that a partial quantity will bridge the gap without the actual regimen and assessment. Keep the access question open until the responsible professional’s decision and required communication are recorded, separately from whether the pharmacy ultimately locates stock.

Learn from repeat shortages without rewriting the formulary blindly

Review recurring queries by the specific cause: an unavailable brand, an uncommon strength, unclear wording, a formulation mismatch or affordability. A count of “substitution requests” alone cannot show which problem the clinic should fix. A local pharmacy’s temporary stock position also should not silently redefine a shared medicine catalogue.

For a fictional week, suppose eight calls include three brand-availability questions, two strength changes, one release-formulation mismatch and two partial supplies. The total is eight queries, not eight approved substitutions. Track accepted, declined and unresolved decisions separately and examine why the same clarification recurs.

When evaluating Bractis, ask to trace one query from the original prescription to the decision and patient communication, with a different actual supply recorded afterward. Verify the current product’s capabilities directly. The purpose is to preserve a reliable clinical and supply history, not to claim an automated interchangeability engine.

Fictional example: the same printed strength conceals a formulation change

A chemist proposes a similarly named product with the same printed strength. The clinic records the complete label and finds a different release formulation. Reception leaves the proposal pending rather than sending a generic approval. The clinician reviews the exact product and documents the decision, and the pharmacy and patient receive the applicable instructions. The case demonstrates why identity verification precedes arithmetic; it does not imply that the fictional products are interchangeable.

Medicine Supply Clarification Review

Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.

Question completeness
Can the reviewer identify both products and the exact difference without another phone call?
Decision authority
Who reviews each type of change under your clinic’s process and applicable requirements?
Patient copy
How are revised instructions, remaining old stock and earlier prescription copies addressed?
Supply evidence
Where do proposed, authorised, dispensed and patient-reported states remain distinct?

Questions doctors ask

Does the same ingredient and strength prove two medicines can be substituted?

No. Formulation, release characteristics, route, additional ingredients, device and patient circumstances may matter. The proposed change needs appropriate professional review using the exact product information.

Can reception approve a chemist’s alternative medicine?

Reception can capture and route the query. Clinical approval must come from an appropriately authorised professional within the applicable rules and clinic process; collecting a product name does not confer that authority.

Can any scored tablet be split to replace an unavailable strength?

Do not assume so. Verify the exact product information, formulation and suitability, then obtain a reviewed instruction. A score line or another brand’s splitting instructions is not sufficient evidence for a different product.

Does a partial pharmacy supply change the prescribed duration?

Not automatically. Record the amount actually supplied and the agreed plan for obtaining the remainder or revising treatment. Any clinical change requires its own decision and instructions.

What if the patient has already taken the alternative?

Establish the actual product and reported use for clinical review, document the advice and correct the applicable plan. A future catalogue or prescription edit cannot substitute for assessing what already happened.

Does approving an alternative for one line replace the whole prescription?

The decision must state its scope. Identify the changed line and which other instructions remain current. A complete revised document can make that relationship clearer than a cropped medicine row. Do not infer that unrelated medicines have stopped or changed because one unavailable product was replaced.

Can a second pharmacy supply any available alternative for the outstanding balance?

Approval is specific to the reviewed product and plan. Share the current prescription and what has already been supplied, then reconcile the proposed balance. If the second pharmacy offers a different product, formulation or strength, obtain the appropriate new review rather than extending the first approval by assumption.

Sources and scope

Updated on . This article combines the cited references with Bractis’s original workflow analysis and illustrative examples. Product capabilities depend on the configured scope. No independent clinical or legal review is claimed.

  • FDA: Tablet Splitting

    Official US HTML page directly read 28 October 2026; no publication or review date was visible in the retrieved page. Supports checking product-specific splitting information and not transferring suitability between brands. It does not establish Indian substitution authority. Individual product labels were not assessed, and no actual splitting method or conversion is prescribed here.

  • NHS SPS: Checking if tablets can be crushed or capsules opened

    Official UK professional guidance directly read 28 October 2026. Published 17 December 2024; last updated 6 February 2025, with the update history identifying a podcast-link addition. Used narrowly for product-information and brand/formulation distinctions. Linked monographs, product labels and podcast were not reviewed. No manipulation instructions, Indian legal authority or real-product equivalence assessment is imported; the shortage case is original fictional analysis.

Try the workflow
with Bractis.

Trace a fictional out-of-stock query through exact product comparison, professional review, revised instructions and confirmation of what the patient actually received.

Request a clinic demo